News | July 20, 2023
M&A activity of pharma CMOs will continue despite challenging borrowing environment, says GlobalData
CMOs showed an increasing reluctance to take on debt in 2022
CMOs showed an increasing reluctance to take on debt in 2022
Diclofenac Sodium and Misoprostol Delayed Release Tablets USP, 50mg/200 mcg and 75mg/200 mcg had annual sales of USD 13 mn in the United States
The company expects this approval in Baddi to pave the way for GMP certifications from European Medicines Agency and other PIC/S member nations
The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans
The acquisition of Medisol is part of Lupin's strategy to expand its presence in the EU
The partnership will commercialize four nasal sprays with a combined Global IQVIA market size in excess of $400m
The company expects the GMP approval from Saudi Food and Drug Authority (SFDA) to soon pave the way for marketing authorizations from the largest market in the GCC region
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
Spiro will be responsible for the overall strategy, implementation and growth of Lupin’s U.S. Generics business
Subscribe To Our Newsletter & Stay Updated
